Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
Cervera J, Montesinos P, Hernández-Rivas JM, Calasanz MJ, Aventín A, Ferro MT, Luño E, Sánchez J, Vellenga E, Rayón C, Milone G, de la Serna J, Rivas C, González JD, Tormo M, Amutio E, González M, Brunet S, Lowenberg B, Sanz MA. Cervera J, et al. Among authors: aventin a. Haematologica. 2010 Mar;95(3):424-31. doi: 10.3324/haematol.2009.013243. Epub 2009 Nov 10. Haematologica. 2010. PMID: 19903674 Free PMC article.
Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
Hoyos M, Nomdedeu JF, Esteve J, Duarte R, Ribera JM, Llorente A, Escoda L, Bueno J, Tormo M, Gallardo D, de Llano MPQ, Martí JM, Aventín A, Mangues R, Brunet S, Sierra J. Hoyos M, et al. Among authors: aventin a. Eur J Haematol. 2013 Sep;91(3):209-218. doi: 10.1111/ejh.12130. Epub 2013 Jul 25. Eur J Haematol. 2013. PMID: 23646898
Genetic abnormalities associated with the t(12;21) and their impact in the outcome of 56 patients with B-precursor acute lymphoblastic leukemia.
Alvarez Y, Coll MD, Ortega JJ, Bastida P, Dastugue N, Robert A, Cervera J, Verdeguer A, Tasso M, Aventín A, Guitart M, Caballín MR. Alvarez Y, et al. Among authors: aventin a. Cancer Genet Cytogenet. 2005 Oct 1;162(1):21-9. doi: 10.1016/j.cancergencyto.2005.02.019. Cancer Genet Cytogenet. 2005. PMID: 16157196
Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML.
García-Dabrio MC, Hoyos M, Brunet S, Tormo M, Ribera JM, Esteve J, Gallardo D, Duarte RF, de Llano MP, Bargay J, Martí-Tutusaus JM, Heras I, Garcia A, Salamero O, Aventin A, Lecrevisse Q, Orfao A, Sierra J, Nomdedéu JF. García-Dabrio MC, et al. Among authors: aventin a. Am J Clin Pathol. 2015 Sep;144(3):484-92. doi: 10.1309/AJCPRL6XSVFMLH9V. Am J Clin Pathol. 2015. PMID: 26276779
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
Perea G, Lasa A, Aventín A, Domingo A, Villamor N, Queipo de Llano MP, Llorente A, Juncà J, Palacios C, Fernández C, Gallart M, Font L, Tormo M, Florensa L, Bargay J, Martí JM, Vivancos P, Torres P, Berlanga JJ, Badell I, Brunet S, Sierra J, Nomdedéu JF; Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel. Perea G, et al. Among authors: aventin a. Leukemia. 2006 Jan;20(1):87-94. doi: 10.1038/sj.leu.2404015. Leukemia. 2006. PMID: 16281071
130 results